First Time Loading...
I

Immuneering Corp
NASDAQ:IMRX

Watchlist Manager
Immuneering Corp
NASDAQ:IMRX
Watchlist
Price: 1.6185 USD 1.16% Market Closed
Updated: May 15, 2024

Immuneering Corp
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Immuneering Corp
Interest Income Expense Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
I
Immuneering Corp
NASDAQ:IMRX
Interest Income Expense
$3.6m
CAGR 3-Years
348%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$1.8B
CAGR 3-Years
8%
CAGR 5-Years
-7%
CAGR 10-Years
-19%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$757m
CAGR 3-Years
35%
CAGR 5-Years
0%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.9B
CAGR 3-Years
-44%
CAGR 5-Years
-30%
CAGR 10-Years
-16%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$563.1m
CAGR 3-Years
78%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$221.8m
CAGR 3-Years
-13%
CAGR 5-Years
75%
CAGR 10-Years
N/A

See Also

What is Immuneering Corp's Interest Income Expense?
Interest Income Expense
3.6m USD

Based on the financial report for Dec 31, 2023, Immuneering Corp's Interest Income Expense amounts to 3.6m USD.

What is Immuneering Corp's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
348%

Over the last year, the Interest Income Expense growth was 257%. The average annual Interest Income Expense growth rates for Immuneering Corp have been 348% over the past three years .